NCT05806645 UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events
| NCT ID | NCT05806645 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Acute Kidney Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 6,046 participants |
| Start Date | 2025-02-12 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6,046 participants in total. It began in 2025-02-12 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Nearly one in ten people who are hospitalized in Canada develop a complication with sudden loss of kidney function, called acute kidney injury (AKI). AKI may lead to other severe health problems after discharge home, such as kidney failure requiring dialysis treatment, heart failure, heart attacks, stroke, and even premature death. Discharge from hospital to home can be a difficult transition where there are often gaps in identification, communication, care coordination, education, and planning of care for AKI. The study team will co-design and evaluate a tailored post-discharge care plan that is based on the risk of later kidney problems and uses currently available, yet untapped digital innovation to improve the health and experience of people with AKI. This study will be built into Alberta's new Epic Systems based provincial electronic health record (EHR). The plan is to use digital tools in the EHR to identify all people in Alberta hospitals that have had an AKI event and are at increased risk of long-term complications. Half will randomly be assigned to receive a tailored care plan based on their risk at hospital discharge while the other half will receive care as it is currently provided by their healthcare team. The electronic health system will automatically calculate a patient's risk and report this risk in their chart along with recommendations for care. The study team includes patients, healthcare providers, and health system decision makers needed to co-develop the proposed strategy and introduce the changes needed to deliver this intervention. The investigators will study whether this strategy can reduce health problems that may happen after AKI including death, chronic kidney disease (CKD), kidney failure, heart attacks, and stroke. The investigators will also determine if the approach improves patient experience during the transition from hospital to home. This study has the potential to revolutionize how we care for people that leave hospital after having AKI.
Eligibility Criteria
Inclusion Criteria: (all of) * Age ≥ 18 years old * Hospitalized at site using AHS EHR * Acute Kidney Injury (Stage 1-3) identified in hospital per KDIGO guideline criteria Exclusion Criteria: (any of) * Pre-hospitalization advanced CKD: eGFR\<30 mL/min/1.73m2 * Pre-hospitalization dialysis * Very low risk (\<1% risk) of advanced CKD * Non-Alberta resident * Palliative goals of care * Enrolled in the UPTAKE VC Trial * Admitted under a nephrologist at time of discharge * Dialysis on at least 2 days in the last week prior to discharge * Receiving apheresis * Kidney transplant recipient * Kidney transplant donor * Diagnosis of Glomerulonephritis * Cirrhosis AND complication of cirrhosis in medical history or active problem list (ascites, varices, hepatic encephalopathy, hepatorenal syndrome)
Contact & Investigator
Neesh Pannu
PRINCIPAL INVESTIGATOR
University of Alberta
Frequently Asked Questions
Who can join the NCT05806645 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05806645 currently recruiting?
Yes, NCT05806645 is actively recruiting participants. Contact the research team at npannu@ualberta.ca for enrollment information.
Where is the NCT05806645 trial being conducted?
This trial is being conducted at Calgary, Canada, Edmonton, Canada.
Who is sponsoring the NCT05806645 clinical trial?
NCT05806645 is sponsored by University of Alberta. The principal investigator is Neesh Pannu at University of Alberta. The trial plans to enroll 6,046 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.